Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1759280 | 0.98 | ACHE (0.56) | ACHEBCHE | |
| SCHEMBL754022 | 0.86 | ACHE (0.46) | ACHEBCHE | |
| SCHEMBL1759365 | 0.79 | GPR84 (0.53) | — | |
| SCHEMBL11960608 | 0.79 | ACHE (0.62) | ACHEBCHE | |
| SCHEMBL5894788 | 0.77 | CYP3A4 (0.41) | ACHEBCHE | |
| SCHEMBL8185340 | 0.76 | ACHE (0.38) | ACHEBCHE | |
| SCHEMBL3696572 | 0.76 | CYP2A6 (0.50) | ACHEBCHE | |
| SCHEMBL16624866 | 0.75 | KCNN2 (0.39) | ACHEBCHE | |
| SCHEMBL21266907 | 0.74 | GPR84 (0.56) | ACHEBCHE | |
| SCHEMBL5894521 | 0.72 | ACHE (0.44) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017147328-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20110294789-A1 | COMPOUNDS FOR RHO KINASE INHIBITION AND FOR IMPROVING LEARNING AND MEMORY | AMNESTIX, INC. | 2011-12-01 | — | — | US | disclosed |
| EP-2332917-A1 | Compounds for PIM kinase inhibition and for treating malignancy | Sygnis Bioscience GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011057784-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2011-05-19 | — | — | WO | disclosed |
| EP-2296472-A1 | COMPOUNDS FOR RHO KINASE INHIBITION AND FOR IMPROVING LEARNING AND MEMORY | Amnestix, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | AMNESTIX, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | AMNESTIX, INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2009151845-A9 | COMPOUNDS FOR RHO KINASE INHIBITION AND FOR IMPROVING LEARNING AND MEMORY | AMNESTIX, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009151845-A1 | COMPOUNDS FOR RHO KINASE INHIBITION AND FOR IMPROVING LEARNING AND MEMORY | AMNESTIX, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | PIM1, PIM2, PIM3 | ACHE 4420/4885BCHE 3898/4885 |
| US-20110294789-A1 | COMPOUNDS FOR RHO KINASE INHIBITION AND FOR IMPROVING LEARNING AND MEMORY | ROCK1, IRAK1, ROCK2 | ACHE 1533/4885BCHE 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.